Key result
Glibenclamide blunts AT1 receptor antagonist-induced coronary vasodilation in preclinical models.
Why the study?
The role of endogenous angiotensin II in maintaining basal coronary artery tone via vascular ATP-sensitive K+ channels was unclear.
Does glibenclamide inhibit coronary vasodilation induced by angiotensin II AT1 receptor antagonists in anesthetized dogs?
Population
Anesthetized dogs
Comparison
Intracoronary infusion of selective angiotensin II AT1 receptor antagonists with vs without glibenclamide or other inhibitors
Design
Preclinical experimental study
Authors
Loading...
Endogenous angiotensin II may modulate basal coronary tone in dogs; leaves open relevance to human CBF.
Does glibenclamide inhibit coronary vasodilation induced by angiotensin II AT1 receptor antagonists in anesthetized dogs?
p-value: p=< 0.01
Endogenous angiotensin II contributes to the maintenance of basal coronary vascular tone by acting at ATP-sensitive K+ channels through its receptors.
Tada et al. (1997) studied this question. Glibenclamide was evaluated on Coronary vasodilation in response to AT1 receptor antagonists (p=< 0.01). Pretreatment with glibenclamide significantly blunted coronary vasodilation in response to AT1 receptor antagonists in anesthetized dogs (p < 0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: